Friday, 16 October 2026European Markets

AHOLD DEL And OENEO Have A High Dividend Yield And Return On Equity In The Consumer Defensive Sector.

Loading stream...

(vianews) - ahold del (ad.as) is among this list of stock assets with the highest dividend rate and return on equity on the consumer defensive sector.

financial asset price forward dividend yield return on equity
ahold del (ad.as) €27.64 4.44% 12.43%
oeneo (sbt.pa) €10.60 3.26% 10.68%

several euronext companies pay out dividends to its shareholders. the dividend yield is a dividend to price ratio showing how much a company pays out in dividends each year.

1. ahold del (ad.as)

4.44% forward dividend yield and 12.43% return on equity

koninklijke ahold delhaize n.v. operates retail food stores and e-commerce primarily in the united states and europe. the company's stores offer produce, dairy, meat, deli, bakery, seafood, and frozen products; grocery, dairy, and beer and wine; floral, pet food, health and beauty care, kitchen and cookware, gardening tools, general merchandise articles, electronics, newspapers and magazines, tobacco, etc.; gasoline; and pharmacy products. it operates its supermarkets, convenience stores, and online stores under the food lion, stop & shop, the giant company, hannaford, giant food, freshdirect, albert heijn, bol.com, etos, gall & gall, delhaize, albert, alfa beta vassilopoulos, mega image, and delhaize serbia brands. the company was formerly known as koninklijke ahold n.v. and changed its name to koninklijke ahold delhaize n.v. in july 2016. koninklijke ahold delhaize n.v. was founded in 1867 and is headquartered in zaandam, the netherlands.

earnings per share

as for profitability, ahold del has a trailing twelve months eps of €1.94.

pe ratio

ahold del has a trailing twelve months price to earnings ratio of 14.25. meaning, the purchaser of the share is investing €14.25 for every euro of annual earnings.

return on equity

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 12.43%.

dividend yield

as maintained by morningstar, inc., the next dividend payment is on apr 12, 2024, the estimated forward annual dividend rate is 1.22 and the estimated forward annual dividend yield is 4.44%.

yearly top and bottom value

ahold del's stock is valued at €27.64 at 16:30 est, way under its 52-week high of €32.51 and above its 52-week low of €25.40.

sales growth

ahold del's sales growth is negative 0.4% for the ongoing quarter and 1.3% for the next.

more news about ahold del.

2. oeneo (sbt.pa)

3.26% forward dividend yield and 10.68% return on equity

oeneo sa operates in the wine industry worldwide. the company manufactures and sale of cork closures. it also provides products and solutions in wine making and spirits. oeneo sa is headquartered in bordeaux, france. oeneo sa operates as a subsidiary of caspar sas.

earnings per share

as for profitability, oeneo has a trailing twelve months eps of €0.52.

pe ratio

oeneo has a trailing twelve months price to earnings ratio of 20.38. meaning, the purchaser of the share is investing €20.38 for every euro of annual earnings.

return on equity

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 10.68%.

revenue growth

year-on-year quarterly revenue growth declined by 10.9%, now sitting on 329.36m for the twelve trailing months.

more news about oeneo.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com